Quirino Lai and Jan Lerut designed the research. Quirino Lai, Alfonso W. Avolio, and Jan Lerut wrote the article. Ivo Graziadei, Gerd Otto, Giuseppe Tisone, Massimo Rossi, Pierre Goffette, Wolfgang Vogel, and Michael B. Pitton participated in the critical evaluation of the article. Quirino Lai performed the data analysis.
Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation
Article first published online: 24 SEP 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 19, Issue 10, pages 1108–1118, October 2013
How to Cite
Lai, Q., Avolio, A. W., Graziadei, I., Otto, G., Rossi, M., Tisone, G., Goffette, P., Vogel, W., Pitton, M. B., Lerut, J. and on behalf of the European Hepatocellular Cancer Liver Transplant Study Group (2013), Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation. Liver Transpl, 19: 1108–1118. doi: 10.1002/lt.23706
The members of the European Hepatocellular Cancer Liver Transplant Study Group include Jan Lerut (chair), Quirino Lai, and Pierre Goffette (Starzl Unit of Abdominal Transplantation, St. Luc University Hospital, Catholic University of Louvain, Brussels, Belgium); Ivo Graziadei and Wolfgang Vogel (Gastroenterology and Hepatology, Department of Internal Medicine II, Innsbruck Medical University, Innsbruck, Austria); Gerd Otto and Michael B. Pitton (Department of Transplantation and Hepatobiliary Surgery, University of Mainz, Mainz, Germany); Pasquale B. Berloco and Massimo Rossi (Department of General Surgery and Organ Transplantation, Umberto I Hospital, Sapienza University, Rome, Italy); Giuseppe Tisone and Tommaso M. Manzia (Department of Transplant Surgery, Polyclinic Tor Vergata Foundation, Tor Vergata University, Rome, Italy); and Salvatore Agnes and Alfonso W. Avolio (Liver Unit, Department of Surgery, Agostino Gemelli Hospital, Catholic University, Rome, Italy).
None of the authors have any conflict of interest to declare.
Quirino Lai was the recipient of a 2012 European Society for Organ Transplantation unrestricted travel grant.
- Issue published online: 24 SEP 2013
- Article first published online: 24 SEP 2013
- Accepted manuscript online: 19 JUL 2013 05:32AM EST
- Manuscript Accepted: 12 JUN 2013
- Manuscript Received: 28 FEB 2013
- 5Liver transplantation for T3 lesions has higher waiting list mortality but similar survival compared to T1 and T2 lesions. Ann Hepatol 2010;9:390-396., , , , .
- 7Liver allocation and distribution: possible next steps. Liver Transpl 2011;17:1005-1012., , .
- 21Sobin LH, Wittekind C, eds. TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002:81-83.
- 26EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol 2011;55:1309-1316., , , , , , .
- 29The Milan criteria: no room on the metro for the king? Liver Transpl 2010;16:252-255., .
- 33European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
- 36How to decide about liver transplantation in patients with hepatocellular carcinoma: size and number of lesions or response to TACE? J Hepatol 2013;59:279–284., , , , , , .
- 39Donor-to-Recipient Italian Liver Transplant (D2R-ILTx) Study Group. Balancing donor and recipient risk factors in liver transplantation: the value of D-MELD with particular reference to HCV recipients. Am J Transplant 2011;11:2724-2736., , , , , , et al.; for